DanGer Shock RCT

DanGer Shock Randomized Controlled Trial (RCT) Confirms Routine Use of Impella® Improves Survival in Heart Attack with Shock1

This independent investigator-initiated study is the first RCT of Impella in cardiogenic shock to complete enrollment. It assessed the efficacy of Impella CP® heart pumps in treating patients with AMICS shock due to STEMI, undergoing emergency PCI.

DanGer Shock RCT Design Infographic showing study design, 3 countries, enrollment numbers and the age range of patients enrolled DanGer Shock RCT Design Infographic showing study design, 3 countries, enrollment numbers and the age range of patients enrolled

Trial Objective:

To determine whether left ventricular (LV) mechanical circulatory support with Impella CP improves survival in patients with STEMI complicated by cardiogenic shock (AMICS) compared to standard care.


Routine Impella CP Use Reduces 180-Day All-Cause Mortality in AMICS Due to STEMI1

The DanGer Shock RCT confirms Impella CP® improves survival by 12.7%, compared to the control arm treated without Impella heart pumps, in heart attack with shock.1 This independent investigator-initiated study represents a landmark as:

  • The first RCT in AMICS trial history to achieve its primary endpoint.1
  • The first RCT in the MCS device trial history to demonstrate a survival benefit in AMICS.1

Patients Randomized 1:1

DanGer Shock RCT Endpoints and Timeframe chart DanGer Shock RCT Endpoints and Timeframe chart

Inclusion Criteria


ST-elevation of the J-point in two contiguous ECG leads ≥0.2 mV in men, or ≥0.15 mV in woman in leads V2-V3, or >0.1 mV in other leads for both genders. In addition patients presenting with STEMI equivalent according to ESC guidelines 2017 with presumed new proximal occlusion of a coronary artery are also a candidate for inclusion.

Cardiogenic Shock

A. Peripheral sign of tissue hypoperfusion with arterial blood lactate ≥2.5 mmol/L or SvO2 < 55%, 
B. Persistent (>30 min) systolic blood pressure less than 100 mmHg and/or need for vasoactive therapy and
C. Left ventricular ejection fraction of less than 45% on echocardiography.


Patients were enrolled at presentation to catheterization laboratory before PCI and up to 12 hours after intervention.

Exclusion Criteria

  • Shock duration >24 hours
  • Other causes of shock; hypovolemia, sepsis, pulmonary embolism or anaphylaxis
  • Shock due to mechanical complication of myocardial infarction; papillary muscle rupture, rupture of the ventricular septum or rupture of ventricular free wall.
  • Severe aortic valve regurgitation/stenosis
  • Severe peripheral arterial obstructive disease that would preclude Impella device placement
  • Mechanical aortic valve prosthesis
  • Already established mechanical circulatory support (Impella or VA-ECMO)
  • Left ventricular thrombus
  • Infective endocarditis
  • Shock due to right ventricular failure
  • Out of hospital cardiac arrest with persistent Glasgow coma scale <8 after return of spontaneous circulation. Cardiac arrest occurring in ambulance or after arrival to hospital is not an exclusion criterion.
  • Subject with documented heparin induced thrombocytopenia.
  • Life expectancy of less than one year due to comorbidities.
  • Mental disorder or language barrier that preclude informed consent.


Other important safety information can be found at


    1. Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med.